Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is a healthcare provider specializing in biopharmaceutical development for metabolic and endocrine disorders, with a promising clinical pipeline including VK2809, VK5211, and VK0214. This positive outlook is supported by efficient oral programs, smaller and shorter studies, a proactive approach towards manufacturing and supply, and the expansion into alternative PBM relationships. Additionally, Viking's strong cash runway, ongoing BD discussions, and potential partnerships further enhance its strategic flexibility and long-term value proposition.

Bears say

Viking Therapeutics is facing potential challenges in patient tolerability with their drug VK2809, as evidenced by high drop-out rates in clinical trials, and are expanding their commercial strategy in hopes of achieving only a 5-10% market share due to anticipated competition. Their quarterly report shows low revenue and high operating expenses, leading to significant net losses.

Viking Therapeutics (VKTX) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 8 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.